Compare Kroger Co (KR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Mesoblast Limited — how do they compare? Kroger Co trades at $56.22 (market cap $34.60B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Kroger Co is far larger — about 16× Mesoblast Limited's market cap, and Kroger Co pays a 2.55% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KR | MESO | |
|---|---|---|
Market Cap | $34.60B | $2.16B |
Sector | Consumer Staples | Technology |
52-Week High | $75.60 | $20.96 |
52-Week Low | $55.53 | $12.88 |
Enterprise Value | $54.70B | $2.17B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.73, down 1.03% with bearish technical signals from moving averages. The company maintains stable revenue around $147B with recent earnings showing mixed results - beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Kroger demonstrates strong cash flow generation with $5.8B from operations in 2025 and pays consistent dividends, while expanding digital services and AI shopping assistance.
Kroger presents a defensive investment opportunity with 2.7% dividend yield and analyst consensus target of $68.63 (21% upside). However, rising debt levels and competitive pressures in grocery retail pose risks. The stock offers value with P/S of 0.25x but trades at premium P/E of 33x, requiring earnings acceleration to justify valuation.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
